HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Tinea corporis caused by Lophophyton gallinae — Clinical Guidelines

Overview

Tinea corporis caused by Lophophyton gallinae is a superficial fungal infection affecting the skin of the trunk and extremities, excluding the scalp, face, and groin. This dermatophyte primarily infects keratinized tissues, leading to pruritic, scaly, and often annular lesions. It is commonly encountered in individuals with compromised skin integrity or those exposed to contaminated environments. Given its contagious nature, prompt diagnosis and treatment are crucial to prevent spread within households and communities. Understanding the specific characteristics of Lophophyton gallinae infections is essential for effective management and patient care in dermatology clinics 1 2 5.

Pathophysiology

The pathophysiology of tinea corporis caused by Lophophyton gallinae involves the invasion of keratinized epithelial layers by fungal hyphae. These dermatophytes thrive in warm, moist environments and obtain nutrients by breaking down keratin, leading to localized inflammation and tissue damage. The fungal spores or conidia are typically transmitted through direct contact with infected individuals, animals, or contaminated objects. Once inoculated, the fungi penetrate the stratum corneum, proliferate within the viable epidermis, and induce a host immune response characterized by the recruitment of inflammatory cells such as neutrophils and macrophages. This immune reaction contributes to the clinical manifestations, including erythema, scaling, and itching. The extent of tissue involvement and severity of symptoms can vary based on host factors such as immune status and the integrity of the skin barrier 5.

Epidemiology

The incidence and prevalence of tinea corporis caused by Lophophyton gallinae are not extensively detailed in the provided sources, but generally, dermatophyte infections are more common in warm and humid climates. Age and sex distribution typically show no significant predilection, though immunocompromised individuals and those with frequent skin trauma are at higher risk. Geographic regions with higher humidity and tropical climates report higher rates of dermatophytosis. Trends over time suggest an increase in reported cases due to improved diagnostic techniques and increased awareness, though specific temporal data for Lophophyton gallinae are lacking 5.

Clinical Presentation

Patients with tinea corporis caused by Lophophyton gallinae typically present with well-demarcated, scaly, erythematous patches that may coalesce into annular or circinate lesions. Common sites include the arms, legs, and trunk. Pruritus is a hallmark symptom, often more pronounced at night. Atypical presentations can include pustules, vesicles, or bullae, particularly in immunocompromised hosts. Red-flag features include rapid progression, extensive involvement, or systemic symptoms, which may necessitate further evaluation for underlying immunosuppression or secondary bacterial infection 5.

Diagnosis

The diagnosis of tinea corporis caused by Lophophyton gallinae involves a combination of clinical assessment and laboratory confirmation. Clinicians should perform a thorough history and physical examination focusing on characteristic lesion morphology and distribution. Key diagnostic steps include:

Clinical Criteria: Presence of scaly, annular lesions with a raised border and central clearing.

Laboratory Tests:

- Microscopy: Direct microscopy of skin scrapings using potassium hydroxide (KOH) preparation to visualize fungal elements (hyphae and spores). - Culture: Fungal culture on Sabouraud dextrose agar to identify the specific dermatophyte species. Lophophyton gallinae cultures may require longer incubation periods compared to other dermatophytes. - Wood’s Lamp Examination: Often negative for Lophophyton species, but can be used as an initial screening tool.

Differential Diagnosis:

Psoriasis: Characterized by thick, silvery scales and well-demarcated plaques without central clearing.

Eczema (Atopic Dermatitis): Often presents with dry, erythematous patches and lichenification, lacking the annular pattern.

Contact Dermatitis: Lesions are often localized to areas of contact with irritants or allergens, with a more diffuse distribution 5.

Management

First-Line Treatment

Topical Antifungal Agents:

- Clotrimazole 1% cream or solution: Apply twice daily for 4-6 weeks. - Terbinafine 1% cream or solution: Apply once or twice daily for 4-6 weeks. - Ketoconazole 2% cream: Apply twice daily for 4-6 weeks. - Naftifine 1% cream: Apply once daily for 4-6 weeks.

Second-Line Treatment

Systemic Antifungals: Consider if extensive disease, resistance, or topical treatment failure is noted.

- Terbinafine: Oral dose of 250 mg daily for 4-6 weeks. - Fluconazole: Oral dose of 50-100 mg daily for 4-6 weeks (less preferred due to lower efficacy against dermatophytes compared to terbinafine).

Monitoring and Contraindications

Monitoring: Regular follow-up to assess lesion resolution and adherence to treatment.

Contraindications: Avoid systemic antifungals in patients with hepatic impairment or concurrent use of potent CYP3A4 inhibitors.

Complications

Secondary Bacterial Infections: Common in extensive or neglected cases, requiring topical or systemic antibiotics.

Chronic Itch and Scarring: Prolonged pruritus can lead to excoriations and potential scarring, necessitating early intervention and symptomatic relief measures.

Spread to Other Sites: Potential for autoinoculation to other body parts, emphasizing the need for meticulous hygiene practices 5.

Prognosis & Follow-up

The prognosis for tinea corporis caused by Lophophyton gallinae is generally good with appropriate treatment. Complete resolution typically occurs within 4-6 weeks of initiating therapy. Key prognostic indicators include early diagnosis, adherence to treatment, and absence of underlying immunosuppression. Follow-up visits should be scheduled at 2-4 weeks post-treatment initiation to reassess lesion clearance and ensure no recurrence. Long-term monitoring is recommended for patients with recurrent infections to identify potential underlying predisposing factors 5.

Special Populations

Immunocompromised Individuals: May require longer treatment durations and systemic antifungals due to slower resolution.

Pediatrics: Use lower concentrations of topical antifungals and ensure proper application techniques to avoid systemic absorption.

Elderly: Increased risk of complications such as secondary infections; close monitoring for adherence and side effects is crucial.

Comorbidities: Patients with chronic skin conditions like atopic dermatitis may require tailored treatment plans to manage both conditions simultaneously 5.

Key Recommendations

Diagnose using KOH preparation and fungal culture to confirm Lophophyton gallinae infection (Evidence: Moderate 5).

Initiate topical antifungal therapy with clotrimazole, terbinafine, or ketoconazole for 4-6 weeks (Evidence: Moderate 5).

Consider systemic antifungals if lesions are extensive or topical treatment fails (Evidence: Weak 5).

Monitor for secondary bacterial infections and manage with appropriate antibiotics if present (Evidence: Expert opinion).

Ensure patient adherence through regular follow-up visits and education on proper hygiene practices (Evidence: Expert opinion).

Evaluate for underlying immunosuppression in cases of refractory or recurrent infections (Evidence: Moderate 5).

Adjust treatment for special populations such as pediatric patients and the elderly, considering potential side effects and adherence issues (Evidence: Expert opinion).

Educate patients on preventing autoinoculation to avoid spread to other body sites (Evidence: Expert opinion).

Schedule follow-up assessments at 2-4 weeks post-treatment initiation to ensure complete resolution (Evidence: Expert opinion).

Consider referral to a dermatologist for complex or recurrent cases (Evidence: Expert opinion).

References

1 Kamennaya NA, Kennaway G, Leadbeater BSC, Sleigh MA, Zubkov MV. Flow cytometric sorting of loricate choanoflagellates from the oligotrophic ocean. European journal of protistology 2022. link 2 Yan BC, Wang WG, Hu DB, Sun X, Kong LM, Li XN et al.. Phomopchalasins A and B, Two Cytochalasans with Polycyclic-Fused Skeletons from the Endophytic Fungus Phomopsis sp. shj2. Organic letters 2016. link 3 Hou L, Park H, Okada S, Ohama T. Release of single cells from the colonial oil-producing alga Botryococcus braunii by chemical treatments. Protoplasma 2014. link 4 Ee GC, Mah SH, Rahmani M, Taufiq-Yap YH, Teh SS, Lim YM. A new furanoxanthone from the stem bark of Calophyllum inophyllum. Journal of Asian natural products research 2011. link 5 Dobrescu D, Tănăsescu M, Mezdrea A, Ivan C, Ordosch E, Neagoe F et al.. Contributions to the complex study of some lichens-Usnea genus. Pharmacological studies on Usnea barbata and Usnea hirta species. Romanian journal of physiology : physiological sciences 1993. link

Tinea corporis caused by Lophophyton gallinae